Latest Vascular endothelial growth factor Stories
CRESTWOOD, Ky., Nov. 20, 2014 /PRNewswire/ -- Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.
LONDON and NEW YORK, November 19, 2014 /PRNewswire/ -- [[CENTER] ]http://www.abmrg.com/Global-Oncology-Market---Trends-Forecast-and-Pipeline-Analysis.html
-- Tanibirumab is a novel VEGFR2-neutralizing mAb for treating cancers SHENYANG, China and DAEJEON, Korea, Nov.
TARRYTOWN, N.Y., Nov. 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd.
ROCKVILLE, Md., Nov.
CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy INDIANAPOLIS, Nov.
Novel Therapies Demonstrating Evidence of Superior Head-to-Head Efficacy Will Expand the Role of Adjunct Therapy, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J., Oct.
Desire for Greater Efficacy and Improved Convenience Drive Perceived Value of Emerging Therapies for Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON,
Ophthotech/Novartis's Fovista Will Exceed $500 Million in 2023 Sales as a Treatment for the Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.